PTC Therapeutics, Inc. (PTCT) Stock: Price, Forecast & Analyst Target
PTC Therapeutics, Inc. (PTCT) — MoonshotScore 32/100 (Weak band), calculated Nov 18, 2026. Price $60.23 (-0.22%), as of the Nov 18, 2026 trading session; market cap $5.03B.
Educational signal · not a buy or sell recommendation · How to read this
PTC Therapeutics, Inc. · PTCT · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: PTC THERAPEUTICS, INC. builds and sells rare-disease medicines, with commercial products such as Translarna, Emflaza, Tegsedi, Waylivra, and Evrysdi, while also running a broader splicing-based R&D program that includes a program for Huntington's disease. Its core question is whether the commercialized rare-disease platform can keep the income base steady while research spending and launch execution move through a high-volatility cycle.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · PTC Therapeutics (PTCT)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but weak growth and a full valuation. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Elite; Financial Safety: Sound; Valuation: Full; Growth Durability: Fading; Momentum: Quiet.
- EPS beat 1 of the last 4 reports
- Altman Z 0.75 · Piotroski F 4
Holding back: soft growth
Helping: business quality
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 35 | Weak | |
| 35 | Weak | |
| 35 | Weak | |
| 35 | Weak | |
| 32 | Weak | |
| 32 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $60.23 | |
| Change on the day | -0.22% | |
| 52-week range | $58.80–$90.87 | |
| Market capitalisation | $5.03B | — |
| Price / earnings (trailing) | 26.35 | |
| Shares traded on the day | 640.6K | |
| Beta (volatility vs the S&P 500) | 0.51 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for PTC Therapeutics (PTCT): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Three of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Klarman-style lens and Moon AI lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is PTC Therapeutics (PTCT), and what does it report?
Short answer · as of
This is a commercializing biopharma model, not a pure discovery story. Revenue comes from marketed product sales, royalty economics, and collaboration or license deals, so any quarter in the packet combines operational drug economics with partner-driven income streams.
Research dated 2026-09-13.
The reported figures therefore measure two things at once: near-term therapeutic commercialization and the monetization of collaborations and regional rights. The quarterly income statement exposes that split through sales, operating and net outcomes, while the annual summary shows how those pieces scale across a full year.
What do the latest results show for PTC Therapeutics (PTCT)?
Research dated 2026-09-13.
The latest reported period in the packet is notably profitable at both operating and net level, while the immediately preceding period remained negative on net, so the business has shifted materially in adjacent windows. Sales were also higher than in that prior window, showing growth at the top line that did not require a narrative of lower expense alone.
Management’s communication channel is visible through the periodic filings: the recent quarterly report and related company notices around results and financial condition provide the official context for that change. In the history of reported guidance versus actuals, outcomes have not been one-directional, so a quarter’s surprise does not lock in a trend by itself.
The estimate history also shows both upside and downside deviations, which means the company’s operating cadence is still being read as eventful rather than stable.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $211M | $16M | $0.20 (diluted) |
| Q4 FY2025 | $165M | -$135M | -$1.71 (diluted) |
| Q1 FY2026 | $273M | -$3M | -$0.03 (diluted) |
| Q2 FY2026 | $361M | $83M | $0.91 (diluted) |
What are the financial strengths and risks for PTC Therapeutics (PTCT)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
Liquidity is a meaningful strength. Cash and short-term investments sit far above debt, and both short-term solvency ratios are supportive, so immediate refinancing pressure is not the dominant constraint.
The cash trend has moved around in recent windows, and operating cash flow has alternated between replenishing and consuming cash even while capital spending has remained relatively contained, so the business still depends on quarter-by-quarter operating strength to convert that balance-sheet cushion into runway.
The bigger vulnerability is not liquidation risk in isolation but quality-of-income deterioration: trailing metrics still show weak net margin context and weaker screening reads, which can turn a strong cash buffer into a temporary bridge if operating momentum fades.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 0.75 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 2 of the last 4 reported quarters.
What should you watch next at PTC Therapeutics (PTCT)?
Short answer · as of
Current published price targets run low $75.00 · high $137.00 · consensus $102.89 · median $104.00 against a quoted price of $60.23 (as of Nov 18, 2026).
Research dated 2026-09-13.
The nearest check is the next quarterly disclosure, where new revenue and earnings figures arrive against existing expectations. That date is already in the filing path, so watch for whether execution keeps the current positive sequence intact.
The concrete test is two-part: whether operational profit and net results hold, and whether operating cash flow stays constructive instead of reverting to a burn phase.
Given prior episodes where reported results moved both above and below expectations, the next read is best treated as an execution signal, not a narrative reset by itself.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does PTC Therapeutics compare with its peers?
Short answer
PTC Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Many rare-disease peers focus on research plus a narrow commercial output, but this company has a distinct footprint with multiple marketed medicines, broad regional commercialization, and explicit royalty and license dependence. That changes the valuation engine from pure pipeline optionality to a blend of access, reimbursement, and contract economics.
Partnership links with large pharmaceutical groups and regional collaborators are therefore not background detail; they are structural to how PTC turns research discoveries into geography-specific revenue streams. If one route stalls, another channel can still support activity, but the reverse is also true when access or partner execution weakens.
| Company | Price | Market value | Score |
|---|---|---|---|
| $315.34 Nov 18, 2026 | $9.34B | 96 5-pillar Nov 18, 2026 | |
| $66.12 Nov 18, 2026 | $9.99B | 90 5-pillar Nov 18, 2026 | |
| $27.61 Nov 18, 2026 | $3.49B | 89 5-pillar Nov 18, 2026 | |
| $41.37 Nov 18, 2026 | $4.53B | 84 5-pillar Nov 18, 2026 | |
| $19.50 Nov 18, 2026 | $5.59B | 83 5-pillar Nov 18, 2026 | |
| $298.71 Nov 18, 2026 | $5.98B | 71 5-pillar Nov 18, 2026 | |
| $13.76 Nov 18, 2026 | $4.83B | 67 5-pillar Nov 18, 2026 | |
| $95.74 Nov 18, 2026 | $6.49B | 67 5-pillar Nov 18, 2026 | |
| $124.86 Nov 18, 2026 | $5.27B | 66 5-pillar Nov 18, 2026 | |
| $156.23 Nov 18, 2026 | $6.35B | 64 5-pillar Nov 18, 2026 | |
| $17.95 Nov 18, 2026 | $3.66B | 63 5-pillar Nov 18, 2026 | |
| $21.89 Nov 18, 2026 | $3.71B | 62 5-pillar Nov 18, 2026 | |
| PTC Therapeutics (PTCT) — this page | $60.23 | $5.03B | 32 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $75.00 – $137.00
- Consensus target
- $102.89
- Median target
- $104.00
Consensus record · Captured .
Measured against a quoted price of $60.23 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 14, 2026
- Transactions
- 92
- Identified insiders
- 8
- Purchases
- 0
- Sales
- 52
- Other transactions
- 40
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held PTCT in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported PTCT in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What Investors Ask About PTC Therapeutics (PTCT) — Healthcare
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Which PTCT therapies and indications are tied to specific regions in the business model?
PTC sells Translarna and Emflaza into Duchenne muscular dystrophy use cases in core regions, with Translarna also reaching additional markets for the nonsense mutation form. Tegsedi and Waylivra are commercialized in Latin America and the Caribbean profile, while Evrysdi is part of the Brazil footprint for pediatric spinal muscular atrophy treatment.
Why does PTCT’s profitability swing so much from one reporting period to the next?
The core cause is visible in the structure itself: commercial sales can be volatile while R&D and commercial overhead remain substantial, and operating results flow directly from that mix. Operating cash flow confirms the same pattern by showing both positive and negative quarters over the recent run. Because of that, one strong quarter does not eliminate near-term downside in the next window.
How long does PTCT’s liquidity story really last if operations cool off?
The company has a large liquid reserve base and a meaningful gap over short-term liabilities, which supports flexibility if commercial timing slips. The condition becomes fragile only when that liquidity is tested by repeated operating cash weakness, since cash history already shows meaningful movement in both directions. That is why the next few quarters matter: funding confidence depends on preserving the cushion while recurring spend stays aligned with execution.
What does ownership activity suggest about near-term pressure on PTCT governance and control?
Institutional presence is broad and includes multiple large holders, so the ownership base is not concentrated in a narrow few. The latest insider activity window, however, was dominated by outbound or non-purchase flows rather than fresh insider buying, which can add interpretive pressure even when it does not by itself change fundamentals. So ownership is stable in breadth, but the composition of insider flow is one of the early signals to monitor.
What is the PTCT stock price today?
The last price recorded for PTC Therapeutics, Inc. (PTCT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the PTCT price target?
The analyst consensus price target for PTC Therapeutics, Inc. (PTCT), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.3-codex-spark) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 23 figures on this page — 1 from SEC filings and earnings calls, 19 from Financial Modeling Prep (FMP), 2 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold PTCT
Funds in our ETF coverage that list PTCT among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| iShares Neuroscience and Healthcare ETF (IBRN) | 3.64% |